's  Instablog
Send Message is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more . Follow on Twitter... More
My company:
Investor Ideas
My blog:
Clean Energy Stocks
  • Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) To Present At SeeThruEquity Investor Conference 0 comments
    Nov 7, 2013 11:05 AM | about stocks: AEMD

    SAN DIEGO - November 7, 2013 ( newswire) Aethlon Medical, Inc. (OTCBB:AEMD), announced today that Company Chairman and CEO, Jim Joyce will present a corporate overview at the SeeThruEquity Investor Conference on November 12th at 10:30 am Eastern Standard Time (EST). Mr. Joyce's presentation will be webcast via the following link: The conference will be held at Convene Midtown East (730 Third Avenue), New York City. Additional details can be accessed online at:

    Aethlon is currently preparing to launch the first U.S. studies of Hemopurifier® therapy based on the recent approval of an Investigational Device Exemption (NYSE:IDE) by the United States Food and Drug Administration (FDA) to initiate feasibility studies in Hepatitis C (HCV) infected individuals.

    On the evening of November 12th, Mr. Joyce will also co-host a grand opening event for the Company's Exosome Sciences, Inc. (NYSE:ESI) subsidiary at 6:30pm EST. Individuals that wish to attend the event should RSVP by email to Chris Wetzel (ESI Director of Operations) by the end of the business day on Friday November 8th. Chris's email address is: The event will be held at the recently established ESI lab located within the Princeton Research Center. The address is 11 Deer Park Drive, Suite 103, Monmouth Junction, NJ 08852. Directions can be accessed online at:

    About Aethlon Medical

    Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit

    Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


    James A. Joyce
    Chairman and CEO
    858.459.7800 x301

    Jim Frakes
    Chief Financial Officer
    858.459.7800 x300

    Marc Robins

    Published at newswire

    Sign up for the free investor news and stock alerts


    Stocks: AEMD
Back To's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


  • #MAGSilver ($MVG, $MAG.TO), #VictoriaGold ($VIT.V) & #ErdeneResourceDevelopment ($ERD.TO) Presentations
    about 24 hours ago
  • Video Release: #SilverCrestMetals Inc (OTC: $SVCMF) at Vancouver Resource Investment Conference 2016 #VRIC16
    3 days ago
  • Video: #SilverCrestMetals Inc. (#TSX: $SIL.V) at Vancouver Resource Investment Conference 2016 #VRIC16
    3 days ago
More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.